One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Judit Molnar, a seasoned pharmaceutical physician and leader, with experience across large pharma and biotech. as a Non-Executive Director. Judit is VP and Head of Early Development, tranScrip, leading the Early Development Team, supporting clients with early development activities from pre-clinical stage to proof-of-concept studies and beyond.   

 

After her medical training, Judit started her career in Academia in the US. Subsequently she relocated to the UK to take up roles in the pharmaceutical industry (Pfizer, GSK), leading early-stage clinical development projects across multiple therapeutic areas. Judit has also held senior level translational medicine roles at biotech companies.  

 

Tony Jones, Chief Executive, One Nucleus explained: “Judit is an excellent addition to the One Nucleus Board. Her extensive experience in drug development, particularly in the translational research and early development stages brings One Nucleus well-informed guidance on the key areas and knowledge gaps where many of our member companies require support. We fully anticipate Judit will play a vital role as we continue the development of One Nucleus as the go to organisation for those seeking to engage with and support Life Sciences in or our region”. 

 

Commenting on their appointment Judit said: “I am delighted to step up my association with One Nucleus and serve our Life Science community.  I am looking forward to working with the talented team and continue what One Nucleus does best; building connections, and helping companies maximise their potential. One Nucleus has some ambitious plans for the future to enable our members to be their best and I look forward to being part of that journey.”